103,912 Shares in Cencora, Inc. (NYSE:COR) Purchased by World Investment Advisors LLC

World Investment Advisors LLC bought a new position in shares of Cencora, Inc. (NYSE:COR) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 103,912 shares of the company’s stock, valued at approximately $23,389,000. World Investment Advisors LLC owned about 0.05% of Cencora at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. New Millennium Group LLC acquired a new stake in shares of Cencora in the second quarter valued at approximately $26,000. MFA Wealth Advisors LLC acquired a new stake in shares of Cencora during the 2nd quarter worth about $30,000. Concord Wealth Partners bought a new stake in shares of Cencora during the 3rd quarter worth about $30,000. SYSTM Wealth Solutions LLC acquired a new position in Cencora in the 2nd quarter valued at about $36,000. Finally, Ashton Thomas Securities LLC acquired a new position in Cencora in the 3rd quarter valued at about $41,000. 97.52% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on COR shares. UBS Group boosted their price objective on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Leerink Partners dropped their target price on Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a report on Monday, October 7th. Mizuho initiated coverage on shares of Cencora in a research note on Wednesday. They issued an “outperform” rating and a $280.00 price target on the stock. Barclays raised their price objective on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Finally, StockNews.com cut shares of Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 20th. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $276.80.

Insider Transactions at Cencora

In related news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the sale, the chairman now directly owns 285,088 shares in the company, valued at $67,223,750.40. This trade represents a 7.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last ninety days, insiders sold 93,018 shares of company stock worth $22,478,942. Corporate insiders own 15.80% of the company’s stock.

Cencora Stock Performance

Cencora stock opened at $243.41 on Friday. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. The stock has a market cap of $47.05 billion, a PE ratio of 32.41, a P/E/G ratio of 1.65 and a beta of 0.45. Cencora, Inc. has a 12-month low of $195.83 and a 12-month high of $253.27. The business’s 50-day moving average price is $237.12 and its two-hundred day moving average price is $233.46.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.90%. This is a boost from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date was Friday, November 15th. Cencora’s dividend payout ratio is currently 29.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.